Back to top
more

bluebird bio (BLUE)

(Real Time Quote from BATS)

$0.33 USD

0.33
5,188,795

-0.03 (-8.99%)

Updated Nov 15, 2024 11:50 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Bluebird Bio (BLUE) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Bluebird (BLUE) delivered earnings and revenue surprises of -31.75% and 86.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 8.18% and 89.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Will Bluebird Bio (BLUE) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why bluebird bio (BLUE) Stock Plunged 60% Year to Date?

by Zacks Equity Research

With no stable stream of income, bluebird bio (BLUE) faces a severe cash crunch. Moreover, the FDA extending the review period of its two regulatory filings also adds fuel to this fire.

bluebird (BLUE) Undertakes Restructuring Moves to Curb Cash Burn

by Zacks Equity Research

bluebird (BLUE) intends to reduce the existing workforce by nearly 30% to reduce 2022 operating expenses by 35-40%. This is likely to generate cost savings of $160 million over two years.

Precigen (PGEN) Up on FDA Fast Track Tag for CAR-T Candidate

by Zacks Equity Research

Precigen (PGEN) is developing CAR T therapy candidate, PRGN-3006 UltraCAR-T, for treating acute myeloid leukemia in a phase I study. The FDA grants Fast Track designation.

bluebird (BLUE) Posts Q4 Loss, Hit by Regulatory Pipeline Woes

by Zacks Equity Research

bluebird (BLUE) reports in-line fourth-quarter 2021 earnings but misses on revenues. The FDA placing clinical holds on BLUE's pipeline candidates does not augur well for the stock.

Bluebird Bio (BLUE) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Bluebird (BLUE) delivered earnings and revenue surprises of 0% and 79.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -21.97% and 607.46%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Bristol Myers' (BMY) Breyanzi sBLA Gets FDA's Priority Review

by Zacks Equity Research

The FDA accepts Bristol Myers' (BMY) sBLA for Breyanzi under a priority review as a second-line treatment for relapsed/refractory large B-cell lymphoma. A decision is due on Jun 24, 2022.

Bluebird Bio (BLUE) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

by Zacks Equity Research

Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Anthem's (ANTM) Q4 Earnings Beat Estimates, Improve Y/Y

by Zacks Equity Research

Anthem's (ANTM) Q4 results reflect better revenues and a solid contribution from its Government Business and IngenioRx businesses, partly offset by escalating expenses.

Is a Beat in Store for HCA Healthcare's (HCA) Q4 Earnings?

by Zacks Equity Research

HCA Healthcare's (HCA) fourth-quarter earnings are likely to have gained from rising admissions and higher revenues.

Anthem (ANTM) Gears Up for Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Anthem's (ANTM) fourth-quarter results are likely to reflect gains from increased premiums and strong membership growth across its Medicare and Medicaid businesses, partly offset by rising expenses.

Biotech Stock Roundup: ZGNX's Acquisition News, REGN, BLUE's Updates & More

by Zacks Equity Research

Regulatory and other pipeline updates from Zogenix (ZGNX) and Regeneron (REGN) are among a few key highlights from the biotech sector during the past week.

bluebird (BLUE) Gene Therapies BLA Decision Delayed, Stock Down

by Zacks Equity Research

The FDA delays decisions dates on bluebird bio's (BLUE) regulatory submissions for beti-cel in thalassemia and eli-cel in cerebral adrenoleukodystrophy by three months.

bluebird's (BLUE) BLA for CALD Therapy Gets Priority Review

by Zacks Equity Research

bluebird's (BLUE) filing for eli-cel, a gene-therapy to treat cerebral adrenoleukodystrophy, gets priority review from the FDA.

Bluebird (BLUE) Loses 20.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

Bluebird (BLUE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

bluebird (BLUE) Filing for Thalassemia Therapy Gets Priority Review

by Zacks Equity Research

bluebird (BLUE) application seeking approval for beti-cel for thalassemia gets priority review in the United States.

Novo Nordisk (NVO) Gets Positive CHMP Opinion for Wegovy

by Zacks Equity Research

The CHMP gives a positive opinion on, and recommends approval to Novo Nordisk's (NVO) Wegovy for chronic weight management in adults with obesity.

bluebird (BLUE) Stock Down 19% on Q3 Earnings & Revenue Miss

by Zacks Equity Research

bluebird (BLUE) reports wider-than-expected loss for third-quarter 2021. It also misses revenue estimates. Shares decline 19% following the announcement.

Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Bluebird (BLUE) delivered earnings and revenue surprises of -7.72% and -59.37%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Bluebird Bio (BLUE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bristol-Myers (BMY) Beats on Q3 Earnings & Sales, Tweaks View

by Zacks Equity Research

Bristol-Myers (BMY) beats on earnings and sales in the third quarter on the back of Revlimid, Eliquis, and Opdivo.

What is in Store for Bristol-Myers (BMY) in Q3 Earnings?

by Zacks Equity Research

Bristol-Myers' (BMY) Q3 earnings might have gained from strong demand for its multiple myeloma drug, Revlimid. Operating expenses might have jumped due to costs associated with the broader portfolio.